Wednesday, 26 August 2026European Markets

SALMAR Stock Was 11.69% Up On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with SALMAR (SALM.OL) jumping 11.69% to kr521.80 on Thursday while Oslo Børs Benchmark Index_GI dropped 0.17% to kr1,219.16.

SALMAR's last close was kr467.20, 36.26% under its 52-week high of kr733.00.

About SALMAR

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming, Sales & Industry, Icelandic Salmon, and SalMar Aker Ocean segments. It is involved in the broodstock, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr29.88.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 17.46. Meaning, the purchaser of the share is investing kr17.46 for every norwegian krone of annual earnings.

Yearly Top and Bottom Value

SALMAR's stock is valued at kr521.80 at 22:41 EST, way under its 52-week high of kr733.00 and way above its 52-week low of kr305.00.

Growth Estimates Quarters

The company's growth estimates for the present quarter is 80.6% and a drop 29.4% for the next.

More news about SALMAR (SALM.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com